Shots:

• The two companies signed a research agreement to discover- develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine's REGENT technology- based on red blood cell extracellular vesicles (RBCEV)
• Carmine to receive upfront- research funding- up to $900M milestones along with royalties on sales of therapies. Following the completion of POC studies- Takeda to get an option to license therapies & will lead development and commercialization activities
• Takeda has committed a $5M convertible loan to support Carmine's REGENT platform. Carmine unveils that its RBCEV-based gene therapy has the potential for repeat dosing- have large transgene payload capacity more than 11KB with enhanced bio-distribution in selected tissues through RBCEV surface modification

Click here to read full press release/ article 

 Ref: PRNewswire | Image:Takeda

Related News: Takeda Collaborates with Codexis to Advance Novel Gene Therapies for Rare Genetic Disorders